US 10,898,494 B2
Dry Powder Treprostinil for the Treatment of Pulmonary HypertensionGeneral
US 10,898,494 B2
Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Celeste A Roney
Art Unit:
1612 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs
Inventors:
Robert Frank Roscigno; Jacob J. Sprague; Brian T. Farrer; Benjamin Maynor
Assignee:
HEALTHCARE ROYALTY PARTNERS IV, L.P., AS SUCCESSOR SUBORDINATED LENDER
Priority:
05/05/17
Filed:
11/05/18
Granted:
01/26/21
Expiration:
05/05/36
Abstract
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Cooperative Patent Classification (CPC)
A61A61P9/12A61K31/5575A61P